|
1
|
Langevin SM, Kratzke RA and Kelsey KT:
Epigenetics of lung cancer. Transl Res. March 12–2014.(Epub ahead
of print).
|
|
2
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006.
|
|
3
|
Xu L, Kikuchi E, Xu C, et al: Combined
EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of
lung cancers codriven by mutant EGFR containing T790M and MET.
Cancer Res. 72:3302–3311. 2012.
|
|
4
|
Witta SE, Jotte RM, Konduri K, et al:
Randomized phase II trial of erlotinib with and without entinostat
in patients with advanced non-small-cell lung cancer who progressed
on prior chemotherapy. J Clin Oncol. 30:2248–2255. 2012.
|
|
5
|
D’Incecco A and Cappuzzo F: Gefitinib for
non-small-cell lung cancer treatment. Expert Opin Drug Saf.
10:987–996. 2011.
|
|
6
|
Costanzo R, Piccirillo MC, Sandomenico C,
et al: Gefitinib in non small cell lung cancer. J Biomed
Biotechnol. 2011:8152692011.
|
|
7
|
Kobayashi T, Takeda M, Marumo S, Koshimo
Y, Teranishi T, Higami Y and Kato M: Long-term gefitinib treatment
of occult lung carcinoma with multiple brain metastases. Lung
Cancer. 80:109–111. 2013.
|
|
8
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010.
|
|
9
|
Tokumo M, Toyooka S, Ichihara S, et al:
Double mutation and gene copy number of EGFR in gefitinib
refractory non-small-cell lung cancer. Lung Cancer. 53:117–121.
2006.
|
|
10
|
Wrona A and Jassem J: The new TNM
classification in lung cancer. Pneumonol Alergol Pol. 78:407–417.
2010.(In Polish).
|
|
11
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004.
|
|
12
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008.
|
|
13
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004.
|
|
14
|
Cortes-Funes H, Gomez C, Rosell R, et al:
Epidermal growth factor receptor activating mutations in Spanish
gefitinib-treated non-small-cell lung cancer patients. Ann Oncol.
16:1081–1086. 2005.
|
|
15
|
Weiss GJ, Liman AK, Allen J, et al:
Squamous cell carcinoma of the lung with metastasis to the GI tract
associated with EGFR exon 19 deletion. Case Rep Med.
2013:8748362013.
|
|
16
|
Fang W, Zhang J, Liang W, et al: Efficacy
of epidermal growth facor receptor-tyrosine kinase inhibitors for
Chinese patients with squamous carcinoma of lung harboring EGFR
mutation. J Thorac Dis. 5:585–592. 2013.
|
|
17
|
Khozin S, Blumenthal GM, Jiang X, et al:
U.S. Food and Drug Administration Approval Summary: Erlotinib for
the first-line treatment of metastatic non-small cell lung cancer
with epidermal growth factor receptor exon 19 deletions or exon 21
(L858R) substitution mutations. Oncologist. May 27–2014.(Epub ahead
of print).
|
|
18
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009.
|
|
19
|
Rosell R, Moran T, Queralt C, et al:
Spanish Lung Cancer Group: Screening for epidermal growth factor
receptor mutations in lung cancer. N Engl J Med. 361:958–967.
2009.
|
|
20
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28(Suppl 1):
S24–S31. 2009.
|
|
21
|
Shigematsu H and Gazdar AF: Mutations of
EGFR in lung cancers and their implications for targeted therapy.
Discov Med. 4:444–447. 2004.
|
|
22
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006.
|
|
23
|
Bean J, Riely GJ, Balak M, Marks JL,
Ladanyi M, Miller VA and Pao W: Acquired resistance to epidermal
growth factor receptor kinase inhibitors associated with a novel
T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clin Cancer Res. 14:7519–7525. 2008.
|
